학술논문

8 hrs Safety Evaluation Of A Multi-Pressure Dial In Eyes With Glaucoma: Prospective, Open-Label, Randomized Study
Document Type
Clinical report
Source
Clinical Ophthalmology. October, 2019, p1947, 7 p.
Subject
California
Language
English
ISSN
1177-5483
Abstract
Purpose: To investigate the safety and tolerability of the multi-pressure dial with a continuous 8-hr duration in subjects with open-angle glaucoma. Design: Prospective, controlled open-label, randomized, single site study. Subjects: Twenty eyes of 10 subjects with open-angle glaucoma were fitted with a multi-pressuredial and randomized to negative pressure application of-10 mmHg in one eye for 8 (continuous) hours and ambient atmospheric pressure in the contralateral eye. Methods: Main safety outcome measures include best-corrected visual acuity (BCVA), intraocular pressure (IOP) changes from baseline after negative pressure application, slit lamp and dilated fundus exam findings, and rate of adverse events. Subjective assessments were administered both hourly during the 8-hr study period and immediately following the study period. Results: There were no statistically significant changes in IOP, BCVA or TBUT immediately following the 8-hr study period or at the 1-week follow-up visit. Patient-reported tolerability was favorable with a mean response of 1.8 [+ or -] 0.4 (scale [right arrow] 1=best, 10 = worst). Subjects also reported positive interest in the MPD as a glaucoma therapy with a mean response of 1.8 [+ or -] 0.5 (scale [right arrow] 1=best, 10 = worst). One adverse event was reported (headache) and resolved at conclusion of the Day 0 visit. Conclusion: The MPD demonstrated favorable safety with key parameters remaining stable after an 8-hr wear with negative pressure. Negative pressure application through the MPD was well tolerated by subjects enrolled in the study. The favorable findings demonstrate the safety of sustained delivery of negative pressure over a continuous, uninterrupted 8-hr duration. Keywords: multi-pressure dial, normal-tension glaucoma, open-angle glaucoma, glaucoma treatment
Introduction Glaucoma remains a leading cause of blindness worldwide. (1) Currently, treatment options primarily target the reduction of intraocular pressure (IOP), currently the sole modifiable risk factor associated with the [...]